The correct way to take dasatinib/tasatinib

The dosage of Dasatinib strictly depends on the patient's disease stage and weight. Correct dosage is the key to ensuring efficacy and reducing the risk of adverse reactions. The recommended starting dose for adults with chronic phase CML is 100 mg orally once a day, while for adults with accelerated phase CML, myeloid or lymphoblastic phase CML and Ph+ ALL, the recommended starting dose is 140 mg orally once a day. Tablets must be swallowed whole and never crushed, cut or chewed to ensure bioavailability and efficacy. Patients can choose to take it in the morning or evening, and can use it with or without food. They can flexibly adjust it according to their own living habits and tolerance, but the dosage should not be changed at will.

Dosage in pediatric patients needs to be adjusted based on body weight and needs to be reviewed regularly. Children weighing 10 to 20 kg take 40 mg orally daily, 20 to 30 kg 60 mg daily, 30 to 45 kg 70 mg daily, and children weighing at least 45 kg take 100 mg once daily. As children gain weight, doses need to be recalculated every three months and adjusted more frequently if necessary to ensure drug concentrations are within a safe and effective range. For pediatric patients with dysphagia, additional medication management plans provided by doctors can be followed, such as liquid preparations or special auxiliary means to ensure complete absorption of the medication.

During the treatment process, patients must strictly follow the doctor's instructions to complete the course of treatment, and are not allowed to increase or decrease the dose on their own. At the same time, patients must undergo regular blood monitoring, liver and kidney function tests, and electrocardiogram assessments to reduce the risk of drug-related adverse reactions. Clinicians will make necessary adjustments to the dose based on the patient's tolerance and disease response to ensure maximum efficacy. Following the correct medication method can not only improve the therapeutic effect, but also prevent potential adverse reactions in the cardiovascular, respiratory and hematopoietic systems to a certain extent, which is an important prerequisite for the safe use of dasatinib.

Reference materials:https://go.drugbank.com/drugs/DB01254